B. Riley Cuts Lantheus (NASDAQ:LNTH) Price Target to $122.00

Lantheus (NASDAQ:LNTH) had its price objective lowered by B. Riley from $127.00 to $122.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. B. Riley’s price target would suggest a potential upside of 24.86% from the stock’s current price. B. Riley also issued estimates for Lantheus’ Q3 2025 earnings at $1.51 EPS.

Several other research analysts have also commented on the company. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. Finally, Truist Financial raised their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Stock Performance

Shares of Lantheus stock opened at $97.71 on Friday. Lantheus has a one year low of $57.92 and a one year high of $126.89. The stock has a market cap of $6.69 billion, a P/E ratio of 16.26 and a beta of 0.38. The stock’s fifty day moving average is $92.67 and its 200 day moving average is $96.58.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Analysts predict that Lantheus will post 6.01 EPS for the current year.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,109 shares of company stock valued at $6,110,806. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new position in Lantheus in the third quarter worth $25,000. Kestra Investment Management LLC purchased a new position in Lantheus in the fourth quarter worth $27,000. Summit Securities Group LLC purchased a new position in Lantheus in the fourth quarter worth $37,000. UMB Bank n.a. grew its holdings in Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares during the last quarter. Finally, Parkside Financial Bank & Trust grew its holdings in Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after purchasing an additional 280 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.